Want to see PGEN full AI Analyst Report?
PGEN Stock Chart & Stats
$7.28
$0.17(3.15%)
At close: 4:00 PM EDT
$7.28
$0.17(3.15%)
Day’s Range― - ―
52-Week Range$3.04 - $8.98
Previous CloseN/A
Volume2.29M
Average Volume (3M)4.80M
Market Cap
$2.45B
Enterprise Value$2.42B
Total Cash (Recent Filing)$38.21M
Total Debt (Recent Filing)$98.34M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 05, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding358,035,250
10 Day Avg. Volume4,492,813
30 Day Avg. Volume4,802,987
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue28.21
Enterprise Value/Gross Profit31.50
Enterprise Value/Ebitda-16.81
Forecast
1Y Price Target
$15.00Price Target Upside106.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.17
Revenue Forecast (FY)$238.71M
Bulls Say, Bears Say
Bulls Say
Rapid PAPZIMEOS Commercial GrowthPAPZIMEOS is showing strong early commercial traction, with quarterly revenue more than doubling sequentially and launch-to-date sales exceeding $78 million. Continued adoption would strengthen Precigen’s revenue base and provide a foundation for funding operations and pipeline development.
Broad Reimbursement AccessCoverage across approximately 315 million lives and a permanent J-code improve reimbursement visibility and reduce access friction for providers. These structural supports can broaden account activation, facilitate patient treatment, and sustain commercial expansion beyond the initial launch period.
Durable Clinical DifferentiationLong-lasting complete responses provide evidence of meaningful clinical durability, which can differentiate PAPZIMEOS in treatment decisions and support physician confidence. Sustained outcomes may also improve the product’s commercial positioning and reinforce the value of Precigen’s therapeutic platform.
Bears Say
Persistent Cash ConsumptionDeeply negative operating and free cash flow indicate that the business has not yet converted reported activity into self-funded operations. Continued cash consumption may require external financing or successful receivable collections, limiting flexibility for pipeline investment and increasing execution risk.
Elevated Leverage And Debt ServiceDebt materially exceeds the company’s equity base, leaving a relatively narrow cushion if losses or cash outflows persist. Ongoing interest expense further reduces financial flexibility, while the higher leverage can constrain capital allocation and increase dependence on successful commercialization.
Margin And Spending PressureThe 95% quarterly gross margin benefited from prelaunch inventory and is expected to decline toward a lower steady-state range. At the same time, commercial and pipeline spending is rising, creating a durable risk that operating costs may absorb more of the product’s gross profit.
Precigen News
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $3.04 and its highest was $8.98 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $2.45B.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Aug 04, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.062.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen does not currently pay dividends.
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is 0.06.
How many shares outstanding does Precigen have?
Precigen has 358,035,250 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 5.513%.
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (106.04% Upside)
$15.00 (106.04% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 95%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 800.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 16.4%
Last 30 Days ▲ 16.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.35%
12-Months-Change
Fundamentals
Return on Equity
-498.32%
Trailing 12-Months
Asset Growth
67.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precigen
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
PGEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for PAPZIMEOS driven by exceptional Q2 revenue growth (>145% QoQ), launch-to-date revenue >$78M, broad payer coverage (~315M lives), durable clinical responses (83% ongoing CR >3 years), and attainment of profitability for the quarter and first half of 2026. Operational and financial risks noted include normalization of gross margins after remaining prelaunch inventory is consumed, reliance on accounts receivable collections and existing debt interest expense, rising commercial and future R&D spend, and limited public granularity on exact account activation counts and non-hub patient visibility. Overall, the positive revenue, profitability, coverage, and durability developments materially outweigh the manageable operational and financial caveats.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$15.00
▲(106.04% Upside)
Technical Analysis
uniQure
―
Intellia Therapeutics
―
Solid Biosciences
―
Obsidian Therapeutics
―
Sana Biotechnology
―
Ownership Overview
35.39% Insiders
11.74% Mutual Funds
0.28% Other Institutional Investors
43.26% Public Companies and
Individual Investors